Does personalized antiplatelet therapy guided by clopidogrel pharmacogenomics improve net clinical benefit in patients with acute ischemic stroke and transient ischemic attack?
Pharmacogenomic-guided personalized antiplatelet therapy improves net clinical benefit in acute ischemic stroke and TIA without increasing bleeding risk.
The present study demonstrates that personalized antiplatelet therapy guided by clopidogrel pharmacogenomics and clinical characteristics can significantly improve the net clinical benefit of ischemic stroke or TIA patients during the 90-day treatment period without increasing bleeding risk.
Zhang et al. (Wed,) studied this question.